-
-
-
-
-
-
-
Elevai Labs (ELAB) Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
-
-
-
-
-
-
-
Merck (MRK) Reports Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival
-
-
-
-
-
-
-
NeuroBo Pharmaceuticals (NRBO) to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June
-
-
-
-
-
-
-
Perspective Therapeutics (CATX) Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
-
-
-
-
-
-
-
Annovis Bio (ANVS) Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
-
-
-
-
-
-
-
Collegium Pharma (COLL) Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA for Nucynta and Nucynta ER
-
-
-
-
-
-
-
Cognition Therapeutics (CGTX) Completes Enrollment in Phase 2 SHIMMER Study of CT1812
-
66,960 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.